Large health industry in 2020 will reach 7.2 trillion | industry chiefs | 'Pathfinder'

Pharmaceutical Network November 27 good news by virtue of force, send me on the Albatron. 'November 24, riding a new era of healthy China's Dongfeng, organized by the Daily Economic News' 2017 China Pharmaceutical (600056, Shares) Capital Forum 'Grand opening in Chengdu.

More than 20 capitalist, industry bigwigs and more than 50 pharmaceutical companies from the country, more than 10 securities investment institutions of the industry elite, shared the annual gluttonous feast of the pharmaceutical industry.

Chinese medicine enterprise Managing Director Guo Yunpei attended the forum and delivered a speech. He mentioned that China is now in an important period of transforming from a big pharmaceutical country to a pharmaceutical power. However, the current situation of China's biomedicine industry in which it is small, scattered and chaotic has not been fundamentally Change.China's pharmaceutical companies are 5.6 times the number of the United States, while the United States each company's sales contribution rate is 5.76 times that of China.

He also said that with the change of the pharmaceutical industry structure, it is predicted that in the next year there will be a major reshuffle and reshuffle of a large-scale industry. After five years, the total number of Chinese biopharmaceutical enterprises will decrease by four points In addition, the current development of China's pharmaceutical listed companies is not balanced, the governance of listed companies need to be improved, so improving the quality of the operation of listed pharmaceutical companies is a lesson in the healthy development of bio-pharmaceutical industry, it is also very important A ring.

Liu Guo'en, a professor of economics at Yangtze University, a professor of economics at Peking University's National Institute of Development, and director of Peking University's China Center for Economic Research, said that the supply side of medical services is still partly in the past due to administrative constraints and resource allocation within the system, Bidding At the same time, under the plan of 'Healthy China', the Chinese people should carry out life-cycle management of their health and should not limit their limited resources to medical services. Environmental protection, education, sports and agriculture should all participate.

China's pharmaceutical industry has entered a new era, the next 5 to 10 years is the key to the development of medicine.State Food and Drug Administration Southern Institute of Pharmaceutical Economics Tao Jianhong, deputy director of that expected health of China 2020, the total scale of China's large-scale health industry will Reached 8% of GDP, the total exceeded 7.2 trillion yuan, the total size will be 2.5 times now.

In recent years, various policies strongly promote the pharmaceutical industry, especially the development of innovative drugs. According to Tao Jianhong, China will usher in a second wave of imported drugs in the future. Under the "two-vote system," the entire drug Circulation industry in the past layers proxy Distribution of distribution patterns will change, the pharmaceutical distribution industry will usher in the reshuffle, the industry consolidation speed, while the field of pension and children, the field of specialty medical food will be the industry's future opportunities.

In recent years, medicine In the field of large consumption increasingly important position, the pharmaceutical industry and capital dance is getting better.

Fu Qiushi, the founding partner of Phoenix Investment, said that in 2017, China ranked 20 in the global biopharmaceutical competitiveness ranking with a score of 58 points for BCI (Biopharmaceutical Competitiveness & Investment), although the biopharmaceutical industry in China However, it is estimated that the average growth rate of China's biopharmaceutical market in 2015-2020 will be 18%, higher than the global growth rate of 12% because of the high level of biopharmaceutical support from China in terms of human resources, capital and policy.

He also mentioned that domestic biopharmaceuticals have subdivided opportunities in antibody and cell therapy, and China needs a sound and sound capital market grading platform to meet the financing needs of innovative pharmaceutical companies in China. In the next five years, there are two biopharmaceutical markets in China Key words: internationalization / innovation / imitation; 'going out' + 'getting in', looking forward to China's future more reasonable and sound direct financing channels + flexible and pragmatic regulatory and policy system.